Surgical oncology

Theralase® Phase II NMIBC Clinical Study (Interim) Data to be Presented at the AUA Annual Meeting

Retrieved on: 
Thursday, February 2, 2023
TLT, Virus, NMIBC, Safety, Patient, Studie II, Trial of the century, Cancer, PDT, Poster, University of Toronto, Metabolic Technologies, Inc., FRCSC, University Health Network, University, American Urological Association, Interim, Princess Margaret Cancer Centre, Bacteria, Surgical oncology, Research, AUA, Pharmaceutical industry, Urology

The AUA annual meeting will take place between April 28th to May 1st, 2023 in Chicago, Illinois with the poster presented for general viewing and discussion within one of the moderated poster sessions, during the AUA annual meeting.

Key Points: 
  • The AUA annual meeting will take place between April 28th to May 1st, 2023 in Chicago, Illinois with the poster presented for general viewing and discussion within one of the moderated poster sessions, during the AUA annual meeting.
  • The poster will include interim clinical data and analysis collected through the enrollment and treatment of patients at all Canadian and US clinical study site by their respective principal investigators for Study II.
  • Arkady Mandel MD, Ph.D., D.Sc., Interim Chief Executive Officer and Chief Scientific Officer, Theralase® stated, “I am delighted that Theralase® will have the opportunity to showcase its latest reported interim clinical data and analysis for Study II at the AUA annual meeting to leading uro-oncologists from around the world.
  • Based on the clinical data collected to date, PDT could represent a viable treatment option with an acceptable safety profile.”

Theralase® Phase II NMIBC Clinical Study (Interim) Data to be Presented at the ASCO GU Cancer Symposium

Retrieved on: 
Wednesday, January 25, 2023
TLT, Virus, Society, NMIBC, Studie II, American Society of Clinical Oncology, Trial of the century, Cancer, Poster, Prostate cancer, University of Toronto, Metabolic Technologies, Inc., Squamous cell carcinoma, FRCSC, University Health Network, University, ASCO, Interim, Princess Margaret Cancer Centre, Bacteria, Surgical oncology, Research, Pharmaceutical industry, Patient, Urology

The GU-ASCO cancer symposium will take place between February 16th to 18th, 2023 in San Francisco, California with the poster presented for general viewing and discussion within Poster Session B: Prostate Cancer and Urothelial Carcinoma on February 17, 2023 at 12:30 PM to 2:00 PM and 5:15 PM to 6:15 PM.

Key Points: 
  • The GU-ASCO cancer symposium will take place between February 16th to 18th, 2023 in San Francisco, California with the poster presented for general viewing and discussion within Poster Session B: Prostate Cancer and Urothelial Carcinoma on February 17, 2023 at 12:30 PM to 2:00 PM and 5:15 PM to 6:15 PM.
  • The poster titled: “A Phase II Clinical Study of Intravesical Photo Dynamic Therapy in Patients with BCG-Unresponsive NMIBC (interim analysis)” will be presented by the lead author, Girish Kulkarni M.D., Ph.D., FRCSC, Divisions of Urology and Surgical Oncology, Department of Surgery, Princess Margaret Cancer Centre, University Health Network, Professor, University of Toronto, (Toronto, Ontario, Canada).
  • The poster will include interim clinical data and analysis collected through the enrollment and treatment of patients at all Canadian and US clinical study site by their respective principal investigators for Study II.
  • Arkady Mandel MD, Ph.D., D.Sc., Interim Chief Executive Officer and Chief Scientific Officer, Theralase® stated, “I am delighted that Theralase® will have the opportunity to showcase its latest reported interim clinical data and analysis for Study II at the coveted ASCO GU Cancer Symposium to leading uro-oncologists from around the world.”

Indian Researchers from ACTREC Discover Novel Therapeutic Agent for a Host of Diseases

Retrieved on: 
Tuesday, January 17, 2023
Neurodegeneration, Cell, Fatality, Atomic energy, Metastasis, DNA damage (naturally occurring), Chromosome, Chromatin, Cytokine, Acral lentiginous melanoma, DNA, Copper, Resveratrol, Surgical oncology, Diarrhea, Treatment, Copper toxicity, Genetically modified bacteria, Emeritus, DNA repair, Protein, Patient, Saliva, Sepsis, Mouse, Bone marrow, Transplant, Research, Vomiting, Serum, Tata Memorial Centre, Inflammation, Incidence, Alzheimer's disease, RESCU, Department of Atomic Energy, ACTREC, Docetaxel, Translational research, Vaccine, TMC, Cancer

MUMBAI, India, Jan. 17, 2023 /PRNewswire/ -- Chromatin comprises a complex mixture of DNA and proteins and forms the structural basis of chromosomes in the cellular nuclei. When cells die, they release cell-free chromatin particles or "cfChPs" into the circulatory system. Emerging evidence indicates that cfChPs exert toxic effects by damaging the DNA of healthy cells and activating pro-inflammatory processes. Researchers from the Advanced Centre for Treatment, Research & Education in Cancer (ACTREC), Tata Memorial Centre (TMC), India, have recently demonstrated therapeutic benefits of a pro-oxidant mixture of resveratrol and copper, R-Cu, in patients undergoing chemotherapy for advanced gastric cancer. Combining R with Cu (R-Cu) leads to the generation of free oxygen radicals which can inactivate the offending cfChPs.

Key Points: 
  • When cells die, they release cell-free chromatin particles or "cfChPs" into the circulatory system.
  • Emerging evidence indicates that cfChPs exert toxic effects by damaging the DNA of healthy cells and activating pro-inflammatory processes.
  • Researchers from the Advanced Centre for Treatment, Research & Education in Cancer (ACTREC), Tata Memorial Centre (TMC), India, have recently demonstrated therapeutic benefits of a pro-oxidant mixture of resveratrol and copper, R-Cu, in patients undergoing chemotherapy for advanced gastric cancer .
  • Combining R with Cu (R-Cu) leads to the generation of free oxygen radicals which can inactivate the offending cfChPs.

University Hospitals in Cleveland Enters into Master Purchase Agreement with ViewRay for Multiple MRIdian® Systems

Retrieved on: 
Thursday, January 5, 2023
Cancer, Prostate cancer, Pancreatic cancer, Radiation, Pancreas, Lung, NCI, Research, News, Irritation, Brain, Physics, Breast, Lustgarten Foundation for Pancreatic Cancer Research, Division, Prostate, Surgical oncology, University Hospitals Cleveland Medical Center, Bladder cancer, Nausea, Patient, Radiosurgery, 2021 Essex County Council election, Physician, Hair loss, U.S. News & World Report, Case Western Reserve University School of Medicine, Kidney, Fatigue, Hospital, Kidney cancer, Magnetic resonance imaging, Cryotherapy, Financial toxicity, Radiofrequency ablation, National Cancer Institute, Radiation therapy, Doctor of Philosophy, Liver, Spine, Medical imaging, Urology, Medicine

DENVER, Jan. 5, 2023 /PRNewswire/ -- ViewRay, Inc. (NASDAQ: VRAY) today announced that the University Hospitals (UH) Seidman Cancer Center in Cleveland has selected a MRIdian MR-Guided Radiation Therapy System as part of a master agreement for the purchase of up to four systems, and will be the first in Ohio at a research and teaching hospital to offer the precision of MRIdian's advanced MRI-guided radiation therapy to cancer patients throughout the region for pancreas, prostate, kidney, gynecological, lung, liver, breast, brain, spine, and oligometastatic cancers.

Key Points: 
  • UH Seidman Cancer Center is part of the NCI-designated Case Comprehensive Cancer Center at Case Western Reserve University School of Medicine.
  • "UH Seidman Cancer Center is at the forefront of clinical excellence and transformative innovation.
  • There was unanimous multi-disciplinary support to bring ViewRay's MRIdian MRI-guided radiotherapy to our center and provide our patients with the latest radiotherapeutic advancements.
  • We aim to continue the advancement of MR-guided adaptive radiotherapy through cutting-edge clinical trials and research to improve patient outcomes.

Beyond Cancer® Publishes Pre-Clinical Data in Cancer Cell International Demonstrating Its Tumor Ablation Method Utilizing Ultra-High Concentration Nitric Oxide (UNO) Induced a Systemic Response that Prevents Metastases

Retrieved on: 
Tuesday, December 13, 2022
Associate, Neoplasm, Annual report, Security (finance), Atmosphere of Earth, Nitric oxide, MD, Toxicity, COVID-19, Policy, Wilms' tumor, Urinary tract infection, Div, Abscopal effect, Respiratory distress syndrome, Pulmonology, FDA, Safety, Cancer, Stanford University School of Medicine, Radiation, Manuscript, NO, Pulmonary hypertension, NTM, GNO, Kaplan–Meier estimator, Nontuberculous mycobacteria, Surgical oncology, UNO, Patient, Immunotherapy, CCI, APC, Hypoxemia, Death, Ultra, Mouse, B cell, Survival, Metastasis, Pharmaceutical industry, Vaccine, Medical imaging, Surgery

The data were published in an article entitled, “Gaseous Nitric Oxide Tumor Ablation Induces an Anti-Tumor Abscopal Effect,” in the peer-reviewed journal Cancer Cell International (“CCI”).

Key Points: 
  • The data were published in an article entitled, “Gaseous Nitric Oxide Tumor Ablation Induces an Anti-Tumor Abscopal Effect,” in the peer-reviewed journal Cancer Cell International (“CCI”).
  • “Beyond Cancer’s novel implementation of ultra-high concentrations of nitric oxide to treat solid tumors has repeatedly resulted in data demonstrating an immunostimulatory response,” stated Dr. Hila Confino, Chief Scientific Officer.
  • Two weeks post gas treatment, the tumors were resected and a week later a secondary tumor was induced in the contralateral flank.
  • In vitro murine data show that local tumor ablation with UNO stimulates an anti-tumor immune response in solid tumor cancer models.

Novian Health Earns New Product Innovation Award for Novilase Breast Therapy

Retrieved on: 
Tuesday, December 6, 2022
Laser, Perception, Annals of Surgical Oncology, Coagulative necrosis, Scar, Breast, Laser medicine, Patient, Frost, Sengupta, Breast cancer, Fatigue, Neoplasm, FDA, Health, Woman, Surgical oncology, Quality of life, Trauma, Cancer, Record, Multimedia, Temperature, Malignancy, Medical imaging, Pharmaceutical industry

CHICAGO, Dec. 6, 2022 /PRNewswire/ -- Novian Health has received Frost & Sullivan's 2022 European New Product Innovation Award in the breast tumor ablation industry for its Novilase® Breast Therapy system. Novilase, a minimally invasive procedure that uses laser ablation to destroy tumors as an alternative to surgery, has the potential to make "the treatment of breast cancer much simpler and more effective, with significantly lower side effects," according to Frost & Sullivan's evaluation.

Key Points: 
  • CHICAGO, Dec. 6, 2022 /PRNewswire/ -- Novian Health has received Frost & Sullivan's 2022 European New Product Innovation Award in the breast tumor ablation industry for its Novilase Breast Therapy system.
  • Novilase is a thermal ablation device that uses laser heat to destroy tumor cells without lumpectomy surgery.
  • "Laser therapy can help patients avoid the trauma and risks of breast cancer surgery," said Henry Appelbaum, president and CEO of Novian Health.
  • "The Novian Health team is proud to receive this award as we begin to offer the benefits of this game-changing technology to breast cancer patients in Europe."

LumaBridge Welcomes Dr. Alexander Stojadinovic as Chief Medical Officer

Retrieved on: 
Tuesday, November 8, 2022
Surgical oncology, MBA, Memorial Sloan Kettering Cancer Center, Hospital, United States service academies, University, Institute, Uniformed Services University of the Health Sciences, Patient, SAN, Bon, Journal of Surgical Oncology, Journal, Program, FACS, Triple accreditation, Drug development, GlaxoSmithKline, MSKCC, Saint Mary's Hospital, Medicine, Maryland School, Walter Reed Army Medical Center, Clinical Medicine Insights: Oncology, Harvard Business School, Partnership, Master of Science, Science, Memorial, European Journal of Cancer, Research, CRO, Outline of health sciences, Health, Strategic planning, Pharmaceutical industry, Management, MD, Cancer, Pharmacy

SAN ANTONIO, Nov. 8, 2022 /PRNewswire/ -- LumaBridge (formerly known as Cancer Insight), a clinical research organization (CRO) dedicated to discovering, developing, and testing emerging biotechnologies related to cancer therapies, welcomes a new chief medical officer, Alexander Stojadinovic, MD, MBA, MSc, FACS.

Key Points: 
  • SAN ANTONIO, Nov. 8, 2022 /PRNewswire/ -- LumaBridge (formerly known as Cancer Insight), a clinical research organization (CRO) dedicated to discovering, developing, and testing emerging biotechnologies related to cancer therapies, welcomes a new chief medical officer, Alexander Stojadinovic, MD, MBA, MSc, FACS.
  • He brings to LumaBridge his extensive experience in strategic planning, program development, team building, operations, and research and development.
  • Dr. Stojadinovic has served as senior medical director in oncology clinical development at GlaxoSmithKline, as medical director of healthcare management services for Amerigroup Texas, and as a consulting surgical oncologist and healthcare executive.
  • "We are thrilled to welcome Alex to the team," said George E. Peoples, MD, FACS, founder, chief scientific officer, and executive chairman of LumaBridge.

Tampa General Hospital Performs 10,000th Robot-Assisted Surgery and Receives Center of Excellence Designation

Retrieved on: 
Tuesday, November 1, 2022
Surgeon, Round Top hospitals, Hospital, Efficiency, Professor, Associate, Anesthesiology, Surgical oncology, Academic health science centre, TGH, University, Tampa General Hospital, News, Adult, Patient safety, CEO, U.S. News & World Report, Health, Safety, Forbes, Trauma, Ducoin v Viamonte, Patient, Infection, Cancer, Digestive system surgery, Tower, Robot-assisted surgery, Risk, Physician, Orthopedic surgery, Nose, Gynaecology, Education, Center of excellence, Intensive care unit, Da Vinci Surgical System, ENT, Woman, State, Obstetrics, Gastroenterology, Pain, Otorhinolaryngology, Neuroscience, Center, GE Healthcare, SRC, Intuition, Home, Fast Track, Accreditation, Dentistry, Medicine, Medical device, Bukkapatnam, Urology

TAMPA, Fla., Nov. 1, 2022 /PRNewswire/ -- Tampa General Hospital (TGH) recently performed its 10,000th robot-assisted surgery. The academic medical center also received accreditation as a Center of Excellence in Robot-Assisted Surgery from the Surgical Review Corporation (SRC), a leading and internationally recognized patient safety organization. This accreditation recognizes Tampa General's commitment to delivering the highest quality, safest and most innovative care available.

Key Points: 
  • TAMPA, Fla., Nov. 1, 2022 /PRNewswire/ -- Tampa General Hospital (TGH) recently performed its 10,000th robot-assisted surgery.
  • The academic medical center also received accreditation as a Center of Excellence in Robot-Assisted Surgery from the Surgical Review Corporation (SRC), a leading and internationally recognized patient safety organization.
  • Tampa General's accreditation as a Center of Excellence in Robot-Assisted Surgery demonstrates its commitment to delivering high standards of quality, safety, and efficiency in patient care.
  • Tampa General Hospital has been designated as a model of excellence by the 2022 Fortune/Merative 100 Top Hospitals list.

GenesisCare and PreludeDx(TM) present compelling Australian-first DCISionRT Study Interim Analysis during Breast Cancer Awareness Month 45% change in treatment recommendations when using DCISionRT

Retrieved on: 
Sunday, October 30, 2022
Royal Melbourne, Hospital, TGA, Breast cancer, Congress, Recurrence, CEO, Doctor of Philosophy, Program, Molecular biology, Radiation, University of California, San Francisco, Woman, Risk, Surgical oncology, Royal Women's Hospital, Cancer, Partnership, Precision medicine, RT, GenesisCare, Biology, Breast, Oncology, DCIS, National, Physician, National Cancer Institute, Research, Technology, University, Interim analysis, Company, BCS, Medical imaging, Pharmaceutical industry, Dentistry, Medicine, Ductal carcinoma, Facebook, Patient

DCIS is a pre-invasive disease of the breast that may lead to invasive breast cancer if untreated.

Key Points: 
  • DCIS is a pre-invasive disease of the breast that may lead to invasive breast cancer if untreated.
  • (2) After breast conserving surgery (BCS) for DCIS, radiation therapy is often used to minimise the risk of recurrence.
  • Radiation therapy recommendation decreased by 70% in patients with a low risk DCISionRT score and increased 29% in patients with elevated risk scores.
  • "GenesisCare, in partnership with PreludeDx, is thrilled to present the interim findings from our Australian-first study," continued Dr Zissiadis.

54 Mercy Medical Center Physicians Named Among Region's "TOP DOCTORS" in November 2022 Issue of BALTIMORE Magazine

Retrieved on: 
Wednesday, October 19, 2022
Institute of Liver and Biliary Sciences, Physician, Pancreatic cancer, Weinberg Center, Bose, Self-signed certificate, University of Maryland School of Medicine, Gynaecology, Health, Twitter, Facebook, Liver cancer, University, Catholic (term), Mercy Hospital, State University of New York Upstate Medical University, The Sisters of Mercy, Maryland School, State university system, Associate, Sister, General surgery, Elective surgery, Center, FACS, Inner Harbor, Surgeon, Medicine, Mercy, Buffalo, Obstetrics, Surgical oncology, Doctor of Philosophy

BALTIMORE,  October 19, 2022 /PRNewswire-PRWeb/ -- A total of 54 Mercy Medical Center physicians were recognized in Baltimore magazine's November 2022 "Top Doctors" issue, representing 28 separate specialties, ranging from dermatology to vascular surgery, specifically:

Key Points: 
  • In addition, Debashish Bose, M.D., PhD, FACS , Medical Director of The Center for Hepatobiliary Disease at Mercy as well as Associate Director of Surgical Oncology at Mercy , was among several physicians photographed and profiled for the special edition.
  • Recognized by Baltimore magazine in Surgical Oncology, Dr. Bose is board certified in General Surgery and offers particular expertise in advanced surgical techniques for pancreatic cancer and liver cancer.
  • Founded in 1874 by the Sisters of Mercy, Mercy Medical Center is located in downtown Baltimore City, about six blocks from Baltimore's famed Inner Harbor.
  • Mercy is home to the renowned Weinberg Center for Women's Health & Medicine, and the $400+ million Mary Catherine Bunting Center.